BTIG Reiterates Buy Rating on Evolus, Inc. (EOLS)
BTIG maintains its buy stance on Evolus with a $13 price target.
Key Points
- BTIG reiterated its buy rating for Evolus, Inc. (EOLS) on June 17, 2026, with a price target of $13.
- Evolus shares are trading at $6.63, with a 52-week range between $3.86 and $10.2, and a market cap of $443.9 million.
- CEO David Moatazedi sold shares in March 2026, and insider transactions were part of planned sales.
BTIG reiterated its buy rating on Evolus, Inc. (NasdaqGM: EOLS) on June 17, 2026. The firm set a price target of $13, suggesting confidence in the company's future performance. Evolus shares are currently trading at $6.63.
Analysts Set New Price Targets
On June 17, 2026, BTIG reiterated its buy rating on Evolus, Inc., maintaining a price target of $13. This aligns with previous ratings, as HC Wainwright & Co. also reiterated a buy rating with a $13 target earlier this year on February 3. Stifel maintained its buy rating with a slightly higher target of $17 on January 13. The consensus among analysts is strong, with a mean price target of $14.67 and a strong buy recommendation from six analysts.
Other Institutional Activity in Evolus
Nantahala Capital Management, LLC increased its holdings in Evolus by 556,208 shares, ending with 6,376,857 shares valued at approximately $26.2 million. BlackRock, Inc. also boosted its position by 195,083 shares to a total of 4,290,383 shares worth about $17.6 million. Meanwhile, Vanguard Capital Management LLC established a position with 2,470,408 shares valued at $10.2 million.
Evolus, Inc. Stock Snapshot
Shares of Evolus, Inc. (NasdaqGM: EOLS) are trading at $6.63. The company has a market capitalization of around $443.9 million and a forward P/E ratio of 25.27. With a beta of 1.334, Evolus has shown some volatility. The stock's 52-week low is $3.86, and its high is $10.2. Its 50-day moving average is $5.88, and the 200-day moving average is $5.91. Evolus maintains a current ratio of 2.04 and a quick ratio of 1.5.
Recent Earnings
Evolus reported revenue of $301.8 million with a growth rate of 6.7%. Despite the revenue increase, the company posted a net margin of -14.39%, reflecting ongoing challenges in achieving profitability. The company is expected to announce its next earnings on August 4, 2026.
Insider Buying and Selling at Evolus, Inc.
In March 2026, CEO David Moatazedi sold 13,669 shares at an average price of $4.75 as part of a planned transaction. Additionally, Chief Medical Officer Rui Avelar sold 3,119 shares at the same price. On March 17, Moatazedi and Avelar executed planned sales of 116,720 and 29,996 shares, respectively, at $4.8883 each.
About Evolus, Inc.
Evolus, Inc. is a healthcare company based in Newport Beach, California. It focuses on performance beauty products, targeting the cash-pay aesthetic market in the U.S., Canada, Europe, and Australia. The company offers Jeuveau, a botulinum toxin type A formulation for improving the appearance of glabellar lines, and Evolysse, a line of injectable hyaluronic acid gels. Led by CEO David Moatazedi, Evolus employs about 350 people.
Bottom Line
BTIG's reiteration of a buy rating for Evolus, Inc. with a $13 target reflects ongoing confidence in the company's potential. Investors watch Evolus closely for its position in the aesthetic market, despite its current unprofitability. This analyst update provides a snapshot of sentiment but remember, 13F filings and analyst ratings are backward-looking and may not reflect the latest positions or market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.